Core Viewpoint - Kintara Therapeutics is advancing its business through a merger with TuHURA Biosciences, aiming to enhance its capabilities in developing cancer therapies while reporting improved financial results for the fiscal year 2024. Recent Corporate Developments - Kintara entered into a definitive merger agreement with TuHURA Biosciences, which is focused on immune-oncology and developing technologies to overcome resistance to cancer immunotherapy [2] - The merger is expected to be completed in mid-October 2024, following stockholder approval received on October 4, 2024 [3] Financial Results Summary - As of June 30, 2024, Kintara reported cash and cash equivalents of approximately $4.9 million, an increase from $1.5 million in the previous year [5][7] - For the three months ended June 30, 2024, Kintara reported a net loss of approximately $2.3 million, a decrease from a net loss of $3.3 million for the same period in 2023, attributed to lower research and development expenses [6] - For the fiscal year ended June 30, 2024, the total net loss was approximately $8.3 million, down from $14.6 million in the previous year [8] Selected Balance Sheet Data - Working capital increased to $3.3 million as of June 30, 2024, compared to $0.2 million in the prior year [7] - Total assets rose to $6.2 million from $4.0 million year-over-year [7] Clinical Development Update - Kintara has initiated an open-label study involving 15 patients for its REM-001 therapy in cutaneous metastatic breast cancer, with four patients dosed as of October 7, 2024 [4] - The majority of the costs for the REM-001 study will be funded by a $2.0 million grant from the National Institutes of Health [4] About Kintara - Kintara is dedicated to developing novel cancer therapies, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer, which has shown an 80% clinical efficacy in previous trials [10][11]

Core Points - Kintara Therapeutics has adjourned its Special Meeting of Stockholders due to not reaching the voting threshold for Proposals 3 and 5, which are related to increasing authorized shares and reincorporation from Nevada to Delaware [2][3] - The Special Meeting will reconvene on October 4, 2024, at 9:00 a.m. Eastern Time [1] - The record date for stockholders entitled to vote remains August 14, 2024, and previously submitted proxies will be voted at the adjourned meeting unless revoked [3] Company Overview - Kintara Therapeutics is focused on developing novel cancer therapies, particularly for patients with unmet medical needs, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [6][7] - The company utilizes a proprietary photodynamic therapy platform, which has shown an 80% clinical efficacy in complete responses for evaluable lesions in CMBC patients [7] - Kintara is headquartered in San Diego, California, and aims to address significant medical needs with reduced risk development programs [6][8] Proposed Merger - Kintara is in the process of a proposed merger with TuHURA Biosciences, which is developing immuno-oncology technologies to overcome resistance to cancer therapies [2][4] - TuHURA's lead product candidate, IFx-2.0, is designed to enhance the effectiveness of checkpoint inhibitors in treating advanced or metastatic Merkel Cell Carcinoma [4] - The merger is contingent upon stockholder approval and the completion of necessary regulatory filings with the SEC [11][12]

Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on proposals necessary for the completion of its merger with TuHURA Biosciences, emphasizing the importance of stockholder approval for the future of the company [1][2][4]. Group 1: Merger Details - The proposed merger with TuHURA requires a "FOR" vote on Proposals 3 & 5 from a majority of Kintara's voting power as of August 14, 2024 [1][2]. - Proposal 3 seeks approval to amend Kintara's Articles of Incorporation to increase the number of authorized shares [4]. - Proposal 5 involves the reincorporation of Kintara from Nevada to Delaware, along with a plan of conversion [5]. Group 2: Voting Information - Stockholders must cast their votes by 11:59 p.m. ET on September 19, 2024, to ensure their votes count [1][6]. - Voting can be done via phone or internet, with specific instructions provided for different platforms [5][6]. Group 3: Company Background - Kintara Therapeutics focuses on developing new therapies for solid tumors, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [9][10]. - The company has a proprietary photodynamic therapy platform that has shown an 80% clinical efficacy in previous trials [10]. Group 4: TuHURA Biosciences Overview - TuHURA is an immuno-oncology company in Phase 3 development, working on technologies to overcome resistance to cancer immunotherapy [7]. - Its lead product candidate, IFx-2.0, aims to enhance the effectiveness of existing treatments like Keytruda® for advanced Merkel Cell Carcinoma [7][8].

Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on the proposed merger with TuHURA Biosciences, which aims to create a combined company focused on advancing a diversified late-stage oncology pipeline [1][3]. Company Overview - Kintara Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to developing novel cancer therapies for patients with unmet medical needs [10][12]. - The company's lead program is REM-001 Therapy, which targets cutaneous metastatic breast cancer (CMBC) and has shown an 80% clinical efficacy rate in previous trials [11]. Merger Details - The merger agreement is an all-stock transaction, with pre-merger Kintara equityholders expected to own approximately 2.85% of the combined company, while pre-merger TuHURA equityholders are expected to own about 97.15% [3]. - The combined entity will operate under the name "TuHURA Biosciences, Inc." and will trade on The Nasdaq Capital Market under the ticker "HURA" [3]. - The transaction is anticipated to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval from both companies [3]. TuHURA Biosciences Overview - TuHURA Biosciences is an immuno-oncology company in the Phase 3 registration stage, developing technologies to overcome resistance to cancer immunotherapy [8]. - The lead candidate, IFx-2.0, is designed to be used alongside Keytruda® for treating advanced or metastatic Merkel Cell Carcinoma [8]. Voting Information - Stockholders must vote by 11:59 p.m. Eastern Time on September 19, 2024, for their votes to count, and those eligible to vote include stockholders as of August 14, 2024 [5][6]. - Voting can be conducted via phone or internet, with specific instructions provided for different platforms [6][7].

Core Viewpoint - TuHURA Biosciences has entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody, which is in development as an immunotherapy for cancer treatment [1][8]. Company Overview - TuHURA Biosciences is a Phase 3 registration-stage immune-oncology company focused on developing technologies to overcome resistance to cancer immunotherapy [1][9]. - Kintara Therapeutics is a biopharmaceutical company dedicated to developing new therapies for solid tumors, with a focus on unmet medical needs [3][22]. Product Development - KVA12123 is a VISTA blocking immunotherapy currently completing clinical trials as both a monotherapy and in combination with Merck's KEYTRUDA® for patients with advanced solid tumors [2][8]. - KVA12123 has shown strong tumor growth inhibition in preclinical models without inducing cytokine release syndrome (CRS) in clinical trials, differentiating it from other therapies targeting VISTA [2][19]. Financial Terms - Under the Agreement, TuHURA will pay Kineta a total of $5 million, with an initial payment of $2.5 million at signing and an additional $2.5 million due by July 15, 2024 [8]. - TuHURA also raised $5 million through a private offering to an existing shareholder to support its operations [8][25]. Strategic Goals - The combined company from the merger of TuHURA and Kintara will focus on advancing personalized cancer vaccines and bi-functional antibody-drug conjugates (ADCs) to address major challenges in current cancer immunotherapy [26][27]. - The merger is expected to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval [26].

Recent Corporate Achievements Kintara's existing stockholders will own approximately 5.5% of combined company's common stock at the closing of the Merger, inclusive of the contingent value right ("CVR") linked to the achievement of enrollment of a minimum of 10 patients in the REM-001 study, with such patients each completing 8 weeks of follow-up on or before December 31, 2025. $31 million subscribed financing by TuHURA in connection with the Merger Agreement expected to provide cash runway into late 2025. ...

Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to . ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission file number 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (State or o ...